Australian Doctor 16th June 2023 16JUNE2023 issue | Page 31

NEW Events Calendar
HOW TO TREAT 31
CF
NEW Events Calendar
ausdoc .
com . au
16
X MONTH JUNE library at www . ausdoc . com . au / therapy-update
2022
2023
LEARN MORE ONLINE Visit our Therapy Update

HOW TO TREAT 31

Excessive thick mucus blocking the airways
Inflamation
Increased mucus secretion
Water NaCl Epidermis
Pancreas
Small intestine
Pancreatic duct
Tracheal muscle
Figure 3 . Organs affected by cystic fibrosis .
Water and NaCl
Sweat contains excess salt
Sweat gland
Vein
To the small intestine
started at diagnosis . In infants and toddlers , this involves providing a mechanical stimulus to the chest wall that creates vibrations in the airways and accentuates airflow to help loosen secretions ; these include chest wall percussions , Swiss ball bouncing and assisted huffing . In the preschool years , children are taught blowing games , including blowing bubbles or playing a recorder , which progresses to blowing against resistance , such as blowing up balloons or blowing into water ( bubble-positive expiratory pressure [ PEP ]). Once children can blow against resistance , it is formalised with a PEP device that can be oscillatory or non-oscillatory . This is the cornerstone of treatment from school age through the lifespan .
Inhaled mucolytics are used as adjuncts to improve secretion clearance with directed techniques . Nebulised 6 % hypertonic saline has been shown to result in improvements in lung function in infants , preschool and school-aged children . 20 , 23 In infants , the use of nebulised hypertonic saline also reduces structural lung disease . 21 Inhaled dry-powder mannitol improves lung function in children and adults with CF , and dornase alfa ( recombinant human deoxyribonuclease I , an enzyme that selectively cleaves DNA ) is effective in improving lung function and reducing pulmonary exacerbations .
24 , 25
The timing of inhaled mucolytics and airway clearance is very important . Short-acting mucolytics , such as hypertonic saline or mannitol , are given immediately before or during airway clearance , whereas long-acting mucolytics ( for example , dornase alfa ), inhaled antibiotics ( for example , tobramycin ), LABAs and ICS are administered after directed clearance . Exercise — particularly moderate – high intensity — is also beneficial in promoting airway clearance ; encourage at least 30 minutes of daily exercise . Cough in CF is generally spontaneous and strong and does not need to be externally elicited .
Diet
In the past , the diet for patients with CF typically focused on high-energy and high-fat intake to meet higher energy requirements . 27 Optimising the growth and nutrition in people with CF positively influences lung function and overall survival . The expert CF dietitian closely monitors patients ’
Figure 4 . Clinical manifestations of cystic fibrosis .
growth , intake , pancreatic enzyme replacement therapy ( PERT ) dosing / adherence in pancreatic insufficiency , sodium and fluid requirements and supplemental energy needs .
About 85 % of those with CF have pancreatic insufficiency . 9 The dietitian tailors individualised PERT dosing according to intake at meal and snack times , and this is adjusted based on growth , intake and gastrointestinal symptoms . PERT should be taken at the start of each meal and snack containing fat . Routine supplementation of fat-soluble vitamins ( A , D , E , K ) is also encouraged , particularly in those who are pancreatic insufficient .
Children with CF lose large amounts of sodium and chloride in their sweat . Additional salt is supplied through diet and / or supplements . Insufficient salt intake can interfere with growth , reduce appetite , cause gastrointestinal symptoms and dehydration . Salt is usually added to food and drink , and a specific dose
is prescribed based on patient size , physical activity and time of year ( people sweat more in the summer months ). If a patient is unable to meet their sodium requirements , the CF team will initiate salt tablets .
In recent decades , the nutritional status and growth of patients with CF have shown marked improvements secondary to adherence to a high-fat diet and the use of CFTR modulators . 28 , 29 The dietary recommendations for patients with CF are moving closer to general population guidelines to prevent overweight and obesity — a new and emerging issue in those with CF . 30 , 31 Studies have shown that children with CF consumed significantly more energy-dense , nutrient-poor foods ( such as fast foods ) to meet dietary targets than controls . 26 This is concerning for the future health of children with CF , who are now expected to survive well into adulthood and will experience other comorbidities . 29
Despite overall improvements in nutritional status , some patients continue to struggle to maintain their weight with a high-energy / high-fat diet . The use of oral supplements and enteral feeding are considered in patients who are persistently underweight . 28
Medications
Pharmacological interventions ( see table 3 ) to address pulmonary manifestations now include agents that target airway mucus and airway surface liquid hydration , as well as antimicrobial therapy , including antibiotic eradication treatment in early infection and protocols for maintenance therapy in chronic infection . 6
CFTR MODULATORS The medications mentioned above minimise the effects of CFTR dysfunction through airway clearance , treatment of complications and infection prophylaxis . CFTR
Maen K Abu Househ , Mikael Häggström : bit . ly / 3NN3p4E
modulators allows restoration of channel function by enhancing or restoring epithelial chloride and bicarbonate transport in people with certain CFTR mutations . 18 There are two types : potentiators , which increase the activity of the transport channels already on the epithelial surface ( for example , ivacaftor ), and correctors , which improve the traffic of the defective protein to the cell membrane ( such as lumacaftor , tezacaftor and elexacaftor ). 18 Those currently PBS approved appear in table 4 .
Trikafta , also known as triple combination therapy , is the newest of the CFTR modulators . Studies have found a significantly decreased frequency of pulmonary exacerbations compared with placebo , as well as substantial improvements in pulmonary function and weight gain . 18 Trikafta became available on the PBS in April 2022 for those aged 12 and older who have at least one F508del